Worldwide vaccination programmes have seen considerable progress in fighting diseases but instability and degradation of the active ingredient can be a major hurdle to their use in developing countries. Martin Scholz (CSO) and Wolfram Altenhofen (VP Business Development), Leukocare, describe a novel approach to stabilising vaccines.
Instability and degradation of the ‘active ingredient’ continue to be major drawbacks in the production, transport and storage of vaccines. A broad range of biophysical methods to characterise vaccine formulations are currently being investigated and it is obvious that there is no single answer to the existing challenges on the formulation side. Finding an ‘optimal’ formulation is still largely empirical.
Researchers at Leukocare, however, have developed a novel approach to stabilising vaccines that has its roots in stabilising biologics in medical device combination products and even allows for terminal sterilisation of biologics by irradiation or ethylene oxide (EtO). The results from the initial investigation into this Stabilising and Protecting Solutions (SPS) platform show that it also provides a powerful way of stabilising vaccines.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.